When the term “gene therapy” comes up, the first thing that comes to mind is often some sort of gene replacement or gene editing (either a DNA correction or disruption) to treat a well-defined Mendelian genetic disorder like sickle cell disease or phenylketonuria—not some broad, genetic, complex condition like inflammation or osteoarthritis. Well, unless you are Diem Nguyen, PhD, CEO of Xalud Therapeutics in New York City.